This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Florida Medical Association and the Florida Society of Pathologists. The Florida Medical Association is accredited by the ACCME to provide continuing medical education for physicians.

The Florida Medical Association designates this live activity for a maximum of 9.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity will be registered to offer Self- Assessment Module (SAMs) credits in the American Board of Pathology’s (ABPath) Maintenance of Certification (MOC) program.

CRITERIA FOR SUCCESS
Statements of credit/participation will be awarded based on the participant’s attendance at each session and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claim credit form at www.flpath.org/claimcme.  If you have questions about this CME/CE activity, please contact the FSP at 904-309-6261. Credit must be claimed by July 29, 2020.

ACTIVITY FORMAT
Live

TARGET AUDIENCE
This activity is designed to meet the needs of practicing physicians, pathologists, and other specialists involved with pathology.

STATEMENT OF NEED
The field of pathology is constantly changing, and many of the most important advances in the field. In the setting of new technology, techniques and advancements in the field, practice gaps are inevitable. As such, pathologists require ongoing educational opportunities to stay current in order to maintain and improve their knowledge and competence in the field.

EDUCATIONAL OBJECTIVES
At the conclusion of this activity, all participants should be able to:

• Recognize histopathologic changes in tumor and normal epithelium after neoadjuvant systemic therapy
• Review the reporting systems for breast specimens after neoadjuvant systemic therapy
• Identify residual carcinoma after systemic therapy
• Recognize diagnostic features of lesions of the breast
• Review of breast cases with squamous metaplasia and metaplastic changes.
• Recognize differential diagnosis for spindle cell proliferations of the breast
• Identify the histopathologic and molecular correlates of vulvar squamous cell carcinoma precursor types
• Identify and properly grade squamo-columnar junction specific cervical squamous intraepithelial lesions. (SIL)
• Recite the spectrum of non-HPV adenocarcinomas in the uterine cervix
• Recognize categories of undifferentiated or poorly differentiated carcinomas of the endometrium
• Identify potential pitfalls in assessing glandular and squamous neoplasia of the vulva
• Distinguish variants of verruciform proliferations of the vulva
• Distinguish adenosarcoma from atypical endometrial polyp
• Recognize criteria for aggressive variants of low grade ovarian serous neoplasia
• Identify the origin and nature of “clear cell” neoplasia in the uterus and peritoneal cavity
• Recognize unusual variants of epithelioid trophoblastic tumors
• Recognize variants of endometrioid and undifferentiated carcinomas of the uterus
• Recognize various pathologic and clinical features of Renal Cell Carcinoma subtypes
• Identify morphology and immunohistochemical analysis tests to appropriately classify Renal Cell Carcinoma (RCC)
• Describe the basics of medical malpractice law and the specific legal criteria that determine medical liability
• Recognize the typical timeline of a medical malpractice lawsuit
• Identify ways to minimize the emotional and psychological impact of a medical malpractice lawsuit on the pathologist and the pathologist's family

COMMERCIAL SUPPORT AND EDUCATIONAL GRANTS
At the time of this printing, full commercial support and education grant information was not available. All commercial support and educational grants will be communicated to attendees in advance of the meeting.

PLANNER DISCLOSURES

The planners of this activity disclosed no financial relationships relevant to the content to be presented with the exception of Marilyn Bui, MD who disclosed the following Grant/Research Support: NCI/NIH Core Support Grant. Consultant: Epizyme, BMS, Hologic, ContexVision. Speaker's Bureau: Physicians Education Resource. Other Financial Support: Travel support to speak on behalf of Digital Pathology Associates

FACULTY DISCLOSURES

The faculty of this activity disclosed no financial relationships relevant to the content to be presented.

DISCLOSURE OF THE FLORIDA MEDICAL ASSOCIATION

It is the policy of the Florida Medical Association (FMA) to ensure independence, objectivity and scientific rigor in all approved CME content. CME faculty must present evidence-based data, clarify off-label product use and disclose all relevant financial relationships to the audience. The ideas and opinions expressed during jointly provided events do not necessarily reflect those of the FMA, and the FMA’s approval of course content for AMA PRA Category 1 Credits™. does not constitute an endorsement of the ideas, positions or statements contained therein.  Every effort has been made to ensure that all information provided by the joint provider is accurate and current. However, FMA does not accept responsibility for errors or omissions and accepts no liability for any resulting loss or damage. Attendees agree to participate in this CME activity with full knowledge and awareness that they waive any claim they may have against the FMA for injury or other damage that may result in any way from their participation in this activity.